Polyhydramnios: A Clinical Review

Definition

Polyhydramnios is a pathological excess of amniotic fluid during pregnancy (3). This diagnosis is not based on subjective clinical assessment but is defined by objective, semi-quantitative ultrasound measurements. The two internationally accepted criteria are an Amniotic Fluid Index (AFI) ≥ 24 cm or a Single Deepest Pocket (SDP) ≥ 8 cm (4, 16). The AFI provides a global assessment of fluid by summing the deepest pockets in four uterine quadrants, while the SDP offers a simpler, quicker measurement of the largest single fluid pocket. While neither method is definitively superior in preventing adverse outcomes, their use provides a standardized, reproducible way to diagnose and monitor the condition.

Once diagnosed, the condition is further classified by severity. This stratification is of paramount clinical importance because it directly correlates with the risk of identifying an underlying fetal or maternal pathology and the likelihood of adverse perinatal outcomes.

  • Mild: AFI 24.0–29.9 cm or SDP 8.0–11.9 cm. This is the most common form and is often idiopathic and benign.

  • Moderate: AFI 30.0–34.9 cm or SDP 12.0–15.9 cm. The likelihood of an underlying cause increases significantly.

  • Severe: AFI ≥ 35.0 cm or SDP ≥ 16.0 cm (4, 36). This category carries the highest risk for both mother and fetus and mandates intensive investigation and surveillance.

Epidemiology

Globally, polyhydramnios is an uncommon but significant complication, affecting approximately 1-2% of all pregnancies (3). The vast majority of these cases, around 65-80%, are classified as mild and may resolve spontaneously (3).

The Malaysian context presents a unique and critical challenge due to the nation's high prevalence of diabetes. A landmark 2021 systematic review revealed a Gestational Diabetes Mellitus (GDM) prevalence of 21.5% among pregnant women in Malaysia, a figure substantially higher than in many Western nations (24). Since uncontrolled maternal diabetes is a leading cause of polyhydramnios, clinicians in Malaysia must maintain a high index of suspicion for GDM in any patient presenting with excess amniotic fluid.

High-Yield Clinical Point: The high background rate of GDM in Malaysia creates a significant risk of diagnostic overshadowing. This is a cognitive bias where a clinician attributes a finding (polyhydramnios) to a common co-existing condition (GDM) and prematurely halts further investigation. For instance, a house officer might see a patient with known GDM and new-onset polyhydramnios and assume it is merely due to poor glycemic control. This assumption can be dangerous, as it may lead to missing a critical underlying fetal anomaly, such as a congenital diaphragmatic hernia or a genetic syndrome (22). Therefore, a core principle of safe practice in Malaysia is that a diagnosis of GDM never negates the need for a comprehensive, detailed fetal anomaly scan to rule out other concurrent causes.

Etiology

A systematic and logical search for an underlying cause is mandatory once polyhydramnios is confirmed. However, it is crucial to recognize that in approximately 50-60% of cases, a comprehensive evaluation will yield no specific maternal, fetal, or placental cause. This is termed idiopathic polyhydramnios and is a diagnosis of exclusion (7). The probability of identifying a cause is directly proportional to the severity of the condition, rising from just 17% in mild cases to over 90% in women with moderate-to-severe polyhydramnios (22).

  • Maternal Causes

    • Diabetes Mellitus (Pre-existing or GDM): This remains the most common identifiable cause. Uncontrolled maternal hyperglycemia leads to fetal hyperglycemia. The resulting high glucose level in the fetal circulation acts as an osmotic diuretic, forcing the fetal kidneys to produce an abnormally large volume of urine, thus increasing the amniotic fluid volume (3).

    • Red Cell Alloimmunization (e.g., Rhesus disease): In this condition, maternal antibodies cross the placenta and destroy fetal red blood cells, causing severe fetal anemia. To compensate, the fetal heart must work much harder to deliver oxygen to the tissues, resulting in a high-output cardiac state. This hyperdynamic circulation increases blood flow to the fetal kidneys, leading to polyuria (9).

  • Fetal Causes

    • Gastrointestinal Obstruction: Any blockage in the upper GI tract prevents the fetus from swallowing and absorbing amniotic fluid, leading to its accumulation. Classic examples include esophageal atresia (a blind-ending esophagus) and duodenal atresia, which may present on ultrasound with the pathognomonic "double bubble" sign (impaired fluid clearance) (9).

    • Central Nervous System (CNS) Anomalies: Severe defects like anencephaly (absence of the brain and skull) or holoprosencephaly disrupt or destroy the higher brain centers that control the complex neuromuscular coordination required for swallowing. The swallowing reflex is therefore absent or profoundly impaired (impaired fluid clearance) (9).

    • Fetal Anemia (Non-immune): Any cause of severe anemia, such as congenital infections (e.g., Parvovirus B19, which attacks red cell precursors), major fetomaternal hemorrhage, or homozygous alpha-thalassemia (hydrops fetalis syndrome), will trigger the same high-output cardiac state and subsequent polyuria seen in alloimmunization (9).

    • Genetic/Chromosomal Syndromes: Trisomy 18 (Edwards syndrome), Trisomy 21 (Down syndrome), and Trisomy 13 (Patau syndrome) are frequently associated with polyhydramnios. This is often due to associated structural defects (e.g., duodenal atresia is common in Trisomy 21) or global neuromuscular dysfunction affecting swallowing. The combination of polyhydramnios with concurrent fetal growth restriction is a major red flag highly suggestive of Trisomy 18 (5).

    • Thoracic/Neck Masses: Large space-occupying lesions can physically compress the esophagus, making swallowing difficult or impossible. Examples include a large congenital diaphragmatic hernia (CDH), a congenital pulmonary airway malformation (CPAM), or a massive cervical teratoma (19).

  • Placental/Multiple Gestation Causes

    • Chorioangioma: This is a large, benign vascular tumor of the placenta. It can act as an arteriovenous shunt, "stealing" a large volume of blood from the fetal circulation and forcing the heart into a high-output state to compensate, leading to polyuria (17).

    • Twin-to-Twin Transfusion Syndrome (TTTS): This serious complication occurs in monochorionic (shared placenta) twin pregnancies. Unbalanced vascular connections in the placenta lead to one twin (the donor) pumping blood to the other (the recipient). The recipient twin becomes hypervolemic and hypertensive, leading to a profound polyuria and severe polyhydramnios in its amniotic sac, while the donor twin becomes anemic and develops oligohydramnios (5).

Pathophysiology

Amniotic fluid volume is maintained by a dynamic and complex equilibrium between fluid production (inflow) and clearance (outflow). The entire volume is recirculated approximately every 24 hours near term, highlighting its active regulation (1). Understanding this balance is key to understanding the disease.

  • Primary Inflow: In the second half of pregnancy, fetal urination is the dominant source of amniotic fluid. The fetal kidneys mature and increase their output steadily, producing between 500 and 1200 mL of hypotonic urine per day at term (1). Fetal lung secretions also contribute a smaller, consistent volume.

  • Primary Outflow: The principal mechanism for fluid removal is fetal swallowing. The term fetus swallows a significant volume of fluid, estimated to be between 210 and 760 mL per day (4). This fluid is then absorbed by the fetal gastrointestinal tract and returned to the fetal circulation. A second, vital pathway is intramembranous absorption, where water and solutes are transported directly across the amniotic membrane into the fetal blood vessels on the placental surface (18).

Polyhydramnios is the logical consequence of a disruption to this equilibrium. The pathology can be simplified into two main mechanisms: impaired fetal swallowing (decreased outflow), leading to a backlog of fluid, or increased fetal urine production (increased inflow), overwhelming the clearance pathways. This pathophysiological framework provides the logical basis for the entire diagnostic workup.

Clinical Presentation

The clinical presentation of polyhydramnios exists on a wide spectrum, from being entirely silent to causing acute maternal distress. The symptoms are directly related to the degree of uterine overdistension and the speed of fluid accumulation.

Diagnostic Clues

  • The most common presentation is an asymptomatic finding discovered during a routine third-trimester ultrasound or when a symphysis-fundal height (SFH) measurement is noted to be more than 3 cm larger than the gestational age in weeks (3). On physical examination, the uterus may feel tense and globally enlarged. It is often difficult to palpate fetal parts or determine the fetal lie, and the fetus may be easily "ballotted" (pushed away and then felt to rebound). Fetal heart sounds may be muffled and difficult to auscultate (20).

Common Symptoms (>50% in moderate-to-severe cases)

  • Dyspnea (shortness of breath): This is a hallmark symptom caused by the enlarged uterus elevating the diaphragm and restricting lung expansion. It can progress from mild breathlessness on exertion to orthopnea (inability to breathe comfortably while lying flat) (3).

  • Abdominal pain or a sensation of uterine tightness: Excessive uterine stretch increases myometrial irritability, which can manifest as constant abdominal discomfort or painful preterm contractions (6).

Less Common Symptoms (10-50%)

  • Significant peripheral edema of the lower limbs, vulva, and anterior abdominal wall due to compression of the inferior vena cava and pelvic veins, which impedes venous return (3).

  • Gastrointestinal discomfort, such as severe heartburn (reflux), indigestion, and constipation, caused by pressure on the stomach and bowels (26).

⚠️ Red Flag Signs & Symptoms

  • Severe, debilitating dyspnea at rest or orthopnea.

  • Painful, regular preterm contractions suggesting established preterm labor.

  • A rapidly increasing abdominal girth over a few days, which suggests acute polyhydramnios and requires urgent investigation.

Complications

The overdistension of the uterus is the root cause of most complications.

  • Maternal:

    • Preterm Labor and PROM: Uterine stretch increases myometrial irritability, a major risk factor for preterm labor and premature rupture of membranes (3, 10).

    • Placental Abruption: During rupture of membranes, the rapid decompression of the uterus can cause the placental surface to shear away from the uterine wall, leading to a catastrophic abruption (3).

    • Postpartum Hemorrhage (PPH): The overstretched uterine muscle fibers (myometrium) have a reduced ability to contract effectively after delivery. This uterine atony is the leading cause of severe PPH, a major cause of maternal mortality (3).

    • Cesarean Delivery: The excess fluid allows the fetus to move freely, leading to a high incidence of unstable lie or malpresentation (e.g., breech, transverse), which often necessitates a cesarean section (10).

  • Fetal:

    • Umbilical Cord Prolapse: This is an obstetric emergency. When the membranes rupture, the sudden gush of a large volume of fluid can carry the umbilical cord down ahead of the presenting part, leading to cord compression and acute fetal hypoxia (3).

    • Macrosomia: Often associated with maternal diabetes, leading to its own set of delivery complications like shoulder dystocia.

    • Perinatal Mortality: The risk is significantly increased, particularly in severe cases or when associated with major congenital anomalies or extreme prematurity (10).

Prognosis

The prognosis is highly dependent on the underlying etiology, the severity of the fluid excess, and the gestational age at onset. Mild, idiopathic polyhydramnios discovered late in the third trimester generally has a favorable outcome (13). Conversely, moderate-to-severe cases, those with an early onset, or those associated with significant fetal anomalies carry a much higher risk of perinatal morbidity and mortality (22). The discovery of a major structural or chromosomal anomaly carries the gravest prognosis.

Differential Diagnosis

The primary differential is for a "large for gestational age" uterus, which is not solely caused by polyhydramnios. A systematic approach is required.

  • Multiple Gestation: This is a key differential that is readily and definitively excluded by a basic ultrasound, which will clearly identify the number of fetuses present.

  • Fetal Macrosomia: In this case, the fetus itself is large for its gestational age, but the amniotic fluid volume (AFI/SDP) is within the normal range. Ultrasound biometry is used to calculate an estimated fetal weight, which can then be plotted on a population-specific growth chart to confirm macrosomia.

  • Uterine Fibroids or Large Ovarian Cysts: Benign pelvic masses can significantly increase the symphysis-fundal height measurement, mimicking a larger pregnancy. Ultrasound is highly effective at identifying these masses and distinguishing them from the gestational sac and fetus. The location of the mass (e.g., an anterior fibroid) can disproportionately affect the clinical measurement.

Investigations

Immediate & Bedside Tests

  • Ultrasound Scan: This is the cornerstone investigation. It is used to confirm the diagnosis by objectively measuring the AFI and/or SDP, to classify the severity (mild, moderate, or severe), and to perform basic fetal biometry to assess growth and rule out multiple gestation (10).

Diagnostic Workup

  • First-Line Investigations:

    • Detailed Fetal Anomaly Scan: This is mandatory in all cases, regardless of maternal glycemic status. It is a comprehensive, systematic anatomical survey performed by a skilled operator to detect structural causes. Key areas of focus include visualizing the fetal stomach bubble (to rule out esophageal atresia), the diaphragm, the four-chamber view of the heart, the kidneys and bladder, and the integrity of the neural tube (10).

    • Maternal Glucose Screening: A formal oral glucose tolerance test (OGTT) or a comprehensive blood sugar profile (BSP) is required to definitively rule out or assess the control of GDM, following local Malaysian CPGs (34).

  • Gold Standard:

    • For detecting underlying chromosomal abnormalities, the gold standard is invasive fetal karyotyping via amniocentesis. The fluid collected can be analyzed for aneuploidies. This test should be offered to all women with polyhydramnios, but is strongly recommended in cases with associated fetal structural anomalies, concurrent fetal growth restriction (a red flag for Trisomy 18), or severe, unexplained polyhydramnios (5).

  • Other Key Tests:

    • Maternal Blood Group & Antibody Screen: This is a simple blood test to identify red cell alloimmunization (e.g., presence of anti-D, anti-Kell antibodies) as a potential cause of fetal anemia (17).

    • TORCH Serology: This is not a routine test. It should only be performed if there are specific ultrasound markers suggestive of congenital infection (e.g., fetal hydrops, intracranial calcifications, hepatosplenomegaly) or a relevant maternal clinical history (17).

Monitoring & Staging

  • Serial Ultrasound Scans: These are typically performed every 2-4 weeks. Their purpose is twofold: to monitor the progression of the amniotic fluid volume and to assess fetal growth velocity, watching for the development of macrosomia or growth restriction (10).

  • Cardiotocography (CTG) / Nonstress Test (NST): Fetal surveillance with CTG is indicated for severe polyhydramnios (AFI ≥ 30 cm), typically performed weekly or bi-weekly from 32 weeks of gestation onwards. This is due to the documented increased risk of stillbirth in this subgroup (10). It is not routinely recommended for the sole indication of mild, idiopathic polyhydramnios.

Management

Management Principles

Management is stratified by severity, underlying cause, gestational age, and the presence of maternal or fetal compromise. The overarching goals are to alleviate severe maternal symptoms, prolong the pregnancy to a safe gestational age, and meticulously plan for and manage potential intrapartum and postpartum complications.

Acute Stabilisation (The First Hour)

This applies to patients presenting with acute and severe symptoms, such as respiratory compromise from a tense, rapidly accumulating polyhydramnios.

  • Breathing: Position the patient sitting upright to allow for maximal diaphragmatic excursion and lung expansion. Administer high-flow oxygen via a non-rebreather mask to maintain maternal SpO2 >94% (the action), which is crucial to prevent maternal and subsequent fetal hypoxia (the rationale).

  • Circulation: Secure two large-bore IV cannulas. While fluid resuscitation is not the primary issue, reliable IV access is vital for the potential administration of tocolytics (if in preterm labor) or for emergency procedures like amnioreduction or delivery.

Definitive Therapy

  • First-Line Treatment (Addressing the Cause):

    • The most effective therapy is to treat the underlying cause. In the common scenario of GDM, optimizing maternal glycemic control through diet, oral hypoglycemic agents, or insulin is paramount. Effective glucose management can reduce fetal osmotic diuresis and often leads to a gradual resolution of the polyhydramnios (13).

  • Palliative Interventions (for severe symptoms or preterm labor):

    • Therapeutic Amnioreduction (Amniodrainage): This is an ultrasound-guided procedure where a needle is inserted into the amniotic sac to drain excess fluid. Typically, 1-1.5 liters are removed slowly (e.g., over 30-60 minutes) to relieve maternal respiratory distress and reduce uterine stretch, which may quell preterm contractions (5). It is crucial to counsel the patient that this is an invasive procedure with significant risks, including PROM, placental abruption, infection, and preterm labor. It is therefore reserved for severe, symptomatic cases where the benefits are felt to outweigh the risks (13).

    • Indomethacin: This NSAID works by inhibiting prostaglandins, which in turn reduces fetal renal blood flow and urine output. Its use is limited to short courses (typically 48-72 hours) and is generally contraindicated after 31-32 weeks of gestation. This is a critical safety point, as after this gestation, there is a high risk of causing premature constriction or closure of the fetal ductus arteriosus, which can lead to persistent pulmonary hypertension of the newborn (13).

Supportive & Symptomatic Care

  • Prescription of H2-receptor antagonists or proton pump inhibitors for severe reflux symptoms.

  • Encouraging rest and use of a left-lateral tilt position to alleviate pressure on the vena cava and improve venous return, which can reduce edema.

Key Nursing & Monitoring Instructions

  • Strict monitoring for signs and symptoms of preterm labor (regular, painful contractions, backache, vaginal discharge).

  • Educating the patient on the critical warning signs that require immediate hospital attendance: a sudden gush of fluid from the vagina (suggesting PROM) or a significant decrease in fetal movements.

  • For inpatients with severe polyhydramnios, hourly monitoring of maternal respiratory rate and oxygen saturation is crucial.

Long-Term Plan & Patient Education

  • Delivery must be planned in a hospital with continuous fetal monitoring capabilities and immediate access to resources for neonatal resuscitation and the management of obstetric emergencies like PPH (20).

  • The patient must be counseled extensively on the increased risks during labor and delivery, particularly the risk of umbilical cord prolapse at the time of membrane rupture and the high risk of postpartum hemorrhage.

When to Escalate

Call Your Senior (MO/Specialist) if:

  • The patient develops any signs of established preterm labor.

  • The patient reports new-onset or progressively worsening shortness of breath, especially at rest.

  • An ultrasound reveals severe polyhydramnios (AFI ≥ 35 cm or SDP ≥ 16 cm) or a rapid increase in fluid volume.

  • A major fetal structural anomaly is suspected or confirmed on ultrasound.

  • There is a non-reassuring CTG trace.

Referral Criteria:

  • All cases of moderate-to-severe polyhydramnios should be co-managed with or referred to a Maternal-Fetal Medicine (MFM) specialist or a senior Consultant Obstetrician for expert counseling and management planning.

  • Delivery should be planned in a tertiary care center with an on-site Neonatal Intensive Care Unit (NICU) if a significant fetal anomaly is diagnosed prenatally.


References

  1. Longo, D. L., Fauci, A. S., Kasper, D. L., Hauser, S. L., Jameson, J. L., & Loscalzo, J. (Eds.). (2018). Harrison's principles of internal medicine (20th ed.). McGraw-Hill Education. https://accessmedicine.mhmedical.com/content.aspx?aid=1160773371

  2. Puri, K., & Gada, D. (2012). Polyhydramnios: An Update. Donald School Journal of Ultrasound in Obstetrics and Gynecology, 6(1), 55-63. https://www.dsjuog.com/doi/10.5005/jp-journals-10009-1086

  3. Kaur, J., & Panthri, P. (2023). Polyhydramnios. In StatPearls. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK562140/

  4. Hamza, A., Herr, D., Solomayer, E. F., & Meyberg-Solomayer, G. (2013). Polyhydramnios: Causes, Diagnosis and Therapy. Geburtshilfe und Frauenheilkunde, 73(12), 1241–1246. https://pmc.ncbi.nlm.nih.gov/articles/PMC3964358/

  5. Children's Minnesota. (n.d.). Polyhydramnios causes & treatment. Retrieved July 15, 2025, from https://www.childrensmn.org/services/care-specialties-departments/fetal-medicine/conditions-and-services/polyhydramnios/

  6. Mayo Clinic. (n.d.). Polyhydramnios - Symptoms and causes. Retrieved July 15, 2025, from https://www.mayoclinic.org/diseases-conditions/polyhydramnios/symptoms-causes/syc-20368493

  7. Abele, H., & Hoopmann, M. (2024). Too Much of a Good Thing: Updated Current Management and Perinatal Outcomes of Polyhydramnios. Journal of Clinical Medicine, 13(9), 2588. https://pmc.ncbi.nlm.nih.gov/articles/PMC11717093/

  8. Gizzo, S., et al. (2022). Transient Polyhydramnios during Pregnancy Complicated with Gestational Diabetes Mellitus: Case Report and Systematic Review. Diagnostics, 12(6), 1340. https://www.mdpi.com/2075-4418/12/6/1340

  9. GLOWM. (n.d.). Polyhydramnios. Retrieved July 15, 2025, from https://www.glowm.com/article/heading/vol-10--common-obstetric-conditions--polyhydramnios/id/409583

  10. MSD Manual Professional Edition. (n.d.). Polyhydramnios. Retrieved July 15, 2025, from https://www.msdmanuals.com/professional/gynecology-and-obstetrics/antenatal-complications/polyhydramnios

  11. Merck Manual Professional Edition. (n.d.). Polyhydramnios. Retrieved July 15, 2025, from https://www.merckmanuals.com/professional/gynecology-and-obstetrics/antenatal-complications/polyhydramnios

  12. JaypeeDigital. (n.d.). Oligohydramnios and polyhydramnios. Retrieved July 15, 2025, from https://www.jaypeedigital.com/eReader/chapter/9781907816703/ch89

  13. Mayo Clinic. (n.d.). Polyhydramnios - Diagnosis and treatment. Retrieved July 15, 2025, from https://www.mayoclinic.org/diseases-conditions/polyhydramnios/diagnosis-treatment/drc-20368494

  14. Dr.Oracle AI. (n.d.). What is the definition of polyhydramnios according to the American College of Obstetricians and Gynecologists (ACOG)? Retrieved July 15, 2025, from https://www.droracle.ai/articles/78495/definition-of-polyhydramnios-acog-

  15. Zable Sport. (n.d.). The relation between causes and onset time of... Retrieved July 15, 2025, from https://article.imrpress.com/journal/CEOG/44/1/10.12891/ceog3335.2017/1575956675294-502937242.pdf

  16. Society for Maternal-Fetal Medicine. (n.d.). Society for Maternal-Fetal Medicine Consult Series #46: Evaluation... Retrieved July 15, 2025, from https://publications.smfm.org/publications/263-society-for-maternal-fetal-medicine-consult-series-46/

  17. NHS Wales. (n.d.). Management of Polyhydramnios. Retrieved July 15, 2025, from https://wisdom.nhs.wales/health-board-guidelines/swansea-bay-maternity-file/management-of-polyhydramniosswansea-bay-maternity-guideline-v11-2022pdf/

  18. Brace, R. A. (2017). Regulation of amniotic fluid volume: insights derived from amniotic fluid volume function curves. American Journal of Obstetrics and Gynecology, 217(5), 554-563. https://pmc.ncbi.nlm.nih.gov/articles/PMC6230884/

  19. The Fetal Medicine Foundation. (n.d.). Polyhydramnios. Retrieved July 15, 2025, from https://fetalmedicine.org/education/fetal-abnormalities/amniotic-fluid/polyhydramnios

  20. Texas Children's Hospital. (n.d.). Polyhydramnios. Retrieved July 15, 2025, from https://www.texaschildrens.org/content/conditions/polyhydramnios

  21. Gomal Journal of Medical Sciences. (n.d.). FREQUENCY, CAUSES AND OUTCOME OF POLYHYDRAMNIOS. Retrieved July 15, 2025, from https://gjms.com.pk/index.php/journal/article/viewFile/145/143

  22. Zulkifli, N. F. M., et al. (2023). Unravelling the unseen threat of polyhydramnios in patients with gestational diabetes mellitus: A case report. Malaysian Family Physician, 18(3), 63-67. https://pmc.ncbi.nlm.nih.gov/articles/PMC10781609/

  23. World Health Organization. (2021). prevalence, risk factors, and actions to address gestational diabetes in selected Southeast Asian countries. https://pmc.ncbi.nlm.nih.gov/articles/PMC8416657/

  24. Lee, K. W., et al. (2021). Gestational Diabetes in Malaysia: A Systematic Review of Prevalence, Risk Factors and Outcomes. Sains Malaysiana, 50(8), 2365-2379. https://www.ukm.my/jsm/pdf_files/SM-PDF-50-8-2021/19.pdf

  25. PubMed. (n.d.). Unravelling the unseen threat of polyhydramnios in patients with gestational diabetes mellitus: A case report. Retrieved July 15, 2025, from https://pubmed.ncbi.nlm.nih.gov/38213388/

  26. March of Dimes. (n.d.). Polyhydramnios. Retrieved July 15, 2025, from https://www.marchofdimes.org/find-support/topics/planning-baby/polyhydramnios

  27. NHS. (n.d.). Polyhydramnios (too much amniotic fluid). Retrieved July 15, 2025, from https://www.nhs.uk/conditions/polyhydramnios/

  28. Cleveland Clinic. (n.d.). Polyhydramnios: Causes, Symptoms, Complications & Treatment. Retrieved July 15, 2025, from https://my.clevelandclinic.org/health/diseases/17852-polyhydramnios

  29. Mosaic Life Care. (n.d.). Polyhydramnios. Retrieved July 15, 2025, from https://www.mymlc.com/health-information/diseases-and-conditions/p/polyhydramnios2/

  30. American Pregnancy Association. (n.d.). Polyhydramnios: High Amniotic Fluid During Pregnancy. Retrieved July 15, 2025, from https://americanpregnancy.org/healthy-pregnancy/pregnancy-complications/polyhydramnios-high-amniotic-fluid/

  31. Cleveland Clinic. (n.d.). Fundal Height: Measurement, What It Means & Accuracy. Retrieved July 15, 2025, from https://my.clevelandclinic.org/health/diagnostics/22294-fundal-height

  32. Perinatology.com. (n.d.). Estimation of Fetal Weight. Retrieved July 15, 2025, from https://perinatology.com/calculators/Estimation%20of%20Fetal%20Weight%20and%20Age.htm

  33. PJMHS. (n.d.). Identification of Factors affecting the Symphysio Fundal Height and Prediction of Low Birth Weight (LBW) during Antenatal Period. Retrieved July 15, 2025, from https://pjmhsonline.com/2021/dec/3678.pdf

  34. Malaysian Family Physician. (2019). CPG UPDATE - Management of diabetes in pregnancy in primary care. Retrieved July 15, 2025, from https://e-mfp.org/wp-content/uploads/2019/12/v14n3-cpg-update.pdf

  35. WebMD. (n.d.). What Is Polyhydramnios? Causes, Symptoms, and More. Retrieved July 15, 2025, from https://www.webmd.com/baby/what-to-know-about-polyhydramnios

  36. Worcestershire Acute Hospitals NHS Trust. (n.d.). POLYHYDRAMNIOS GUIDELINE. Retrieved July 15, 2025, from https://apps.worcsacute.nhs.uk/KeyDocumentPortal/Home/DownloadFile/2396

 
Previous
Previous

A Clinical Review of Miscarriage

Next
Next

A Clinical Review of the Larger-Than-Dates Uterus